Repligen Overview

  • Year Founded
  • 1981

Year Founded

  • Status
  • Public

  • Employees
  • 2,000

Employees

  • Stock Symbol
  • RGEN

Stock Symbol

  • Investments
  • 18

  • Share Price
  • $163.70
  • (As of Friday Closing)

Repligen General Information

Description

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 41 Seyon Street, Building 1
  • Suite 100
  • Waltham, MA 02453
  • United States
+1 (781)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 41 Seyon Street, Building 1
  • Suite 100
  • Waltham, MA 02453
  • United States
+1 (781)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Repligen Stock Performance

As of 20-Nov-2026, Repligen’s stock price is $163.70. Its current market cap is $10.5B with 63.9M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$163.70 $170.29 $100.99 - $198.87 $10.5B 63.9M 1.17M -$0.20

Repligen Financials Summary

As of 30-Sep-2026, Repligen has a trailing 12-month revenue of $806M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 10,729,112 9,163,922 7,952,994 9,793,942
Revenue 805,610 738,256 634,439 632,362
EBITDA 127,407 180,852 80,258 145,324
Net Income (11,804) 48,894 (25,514) 35,596
Total Assets 2,926,408 2,949,699 2,829,666 2,831,185
Total Debt 692,241 689,948 686,247 711,804
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Repligen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Repligen‘s full profile, request access.

Request a free trial

Repligen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessi
Biotechnology
Waltham, MA
2,000 As of 2025

Lexington, MA
 

Oklahoma City, OK
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Repligen Competitors (67)

One of Repligen’s 67 competitors is Agenus, a Formerly VC-backed company based in Lexington, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Agenus Formerly VC-backed Lexington, MA
Cytovance Biologics Formerly PE-Backed Oklahoma City, OK
BioAtla Formerly VC-backed San Diego, CA
Merck & Co. Corporation Rahway, NJ
Laysan Bio Private Equity-Backed Arab, AL
You’re viewing 5 of 67 competitors. Get the full list »

Repligen Patents

Repligen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026136802-A2 Affinity ligands for purification of herpesvirus vaccine antigens Pending 20-Dec-2024
WO-2026136802-A3 Affinity ligands for purification of herpesvirus vaccine antigens Pending 20-Dec-2024
WO-2026136475-A2 Equalized tangential flow filtration Pending 18-Dec-2024
WO-2026136475-A3 Equalized tangential flow filtration Pending 18-Dec-2024
WO-2026122755-A1 Kappa light chain affinity ligands Pending 04-Dec-2024 C07K14/00
To view Repligen’s complete patent history, request access »

Repligen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Repligen Investments & Acquisitions (18)

Repligen’s most recent deal was a Merger/Acquisition with Biolife Solutions for . The deal was made on 06-Oct-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Biolife Solutions 06-Oct-2026 Merger/Acquisition Discovery Tools (Healthcare)
908 Devices (Bioprocessing Process Analytical Technology Portfolio) 04-Mar-2025 Corporate Asset Purchase Buildings and Property
Tantti 02-Dec-2024 Merger/Acquisition Biotechnology
Metenova 02-Oct-2023 Merger/Acquisition Medical Supplies
FlexBiosys 17-Apr-2023 Merger/Acquisition Industrial Supplies and Parts
You’re viewing 5 of 18 investments and acquisitions. Get the full list »

Repligen ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

17.6 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Laboratory Equipment and Services

Subindustry

of 67

Rank

Percentile

To view Repligen’s complete esg history, request access »

Repligen Exits (1)

Repligen’s most recent exit was on 01-Jul-2021 from Polymem. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Polymem 01-Jul-2021 Completed
To view Repligen’s complete exits history, request access »

Repligen Affiliates

Subsidiaries (7)

Name Industry Location Year Founded
Tantti Taoyuan, Taiwan 2014
Novozymes Biopharma Sweden Lund, Sweden 2011
Engineered Molding Technology Clifton Park, NY 2010
FlexBiosys San Jose, CA 2009
Metenova Molndal, Sweden 2009
You’re viewing 5 of 7 affiliates. Get the full list.  »

Repligen FAQs

  • When was Repligen founded?

    Repligen was founded in 1981.

  • Where is Repligen headquartered?

    Repligen is headquartered in Waltham, MA.

  • What is the size of Repligen?

    Repligen has 2,000 total employees.

  • What industry is Repligen in?

    Repligen’s primary industry is Biotechnology.

  • Is Repligen a private or public company?

    Repligen is a Public company.

  • What is Repligen’s stock symbol?

    The ticker symbol for Repligen is RGEN.

  • What is the current stock price of Repligen?

    As of 20-Nov-2026 the stock price of Repligen is $163.70.

  • What is the current market cap of Repligen?

    The current market capitalization of Repligen is $10.5B.

  • What is Repligen’s current revenue?

    The trailing twelve month revenue for Repligen is $806M.

  • Who are Repligen’s competitors?

    Agenus, Cytovance Biologics, BioAtla, Merck & Co., and Laysan Bio are some of the 67 competitors of Repligen.

  • What is Repligen’s annual earnings per share (EPS)?

    Repligen’s EPS for 12 months was -$0.20.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process